OncoTargets and Therapy (Mar 2019)
Research status and progress of the RNA or protein biomarkers for prostate cancer
Abstract
Chunjiao Song,1 Huan Chen,2 Chunyu Song3 1Medical Research Center, Shaoxing People’s Hospital/Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang Province, China; 2Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou, Zhejiang, China; 3Department of Anesthesia, The Second Clinical Hospital of Harbin Medical University, Harbin, Heilongjiang, China Abstract: Prostate cancer is a kind of male malignancy. Recently, a large number of studies have reported many potential biomarkers for the diagnosis and prognosis of prostate cancer. In this literature review, we have collected a number of potential biomarkers for prostate cancer reported in the last 5 years. Among them, some are undergoing Phase III clinical trials, and others have been approved by the US Food and Drug Administration. However, most are still in the period of basic research. The review will contribute to future research to find the biomarkers to guide clinicians to make personalized treatment decisions for each prostate cancer patient. Keywords: lncRNAs, microRNAs, fusion gene, TMPRSS2-ERG, methylation
